ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CTMX vs OVID // EV/EBITDA & P/E VALUATION

CytomX Therapeutics Inc. (NASDAQ) VS. Ovid Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CTMX 3 — OVID 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTMX VS. OVID) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CTMX OVID SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -20.50% -28.50% +8.00 CTMX /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -15.19% -7.67% -7.52 OVID /fcf-yield <GO>
Operating Margin -29.30% -60.00% +30.70 CTMX /operating-margins <GO>
Net Profit Margin -22.80% -60.00% +37.20 CTMX /net-margins <GO>
Revenue Growth (YoY) -44.80% 180.00% -224.80 OVID /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 11.46 -11.26 OVID /balance-sheet <GO>
Piotroski F-Score Quality 1/9 3/9 -2.00 OVID /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 42.7 56.1 -13.41 OVID /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $499.0M $500.0M -$973.2K OVID /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CTMX REV OVID REV CTMX GROSS % OVID GROSS % CTMX FCF OVID FCF
FY 2025 $76.2M $7.3M — — -$75.8M -$38.3M
FY 2024 $138.1M $566.0K — — -$86.5M -$56.0M
FY 2023 $101.2M $392.0K — — -$56.0M -$45.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTMX // BETA —
OVID // BETA —